AADAC Polyclonal Antibody
Product Specifications
Background
Microsomal arylacetamide deacetylase competes against the activity of cytosolic arylamine N-acetyltransferase, which catalyzes one of the initial biotransformation pathways for arylamine and heterocyclic amine carcinogens. Arylacetamide deacetylation is an important enzyme activity in the metabolic activation of arylamine substrates to ultimate carcinogens. Displays major serine hydrolase activity in liver microsomes. Hydrolyzes also flutamide, which is an antiandrogen drug used for the treatment of prostate cancer that occasionally causes severe hepatotoxicity. Displays cellular triglyceride lipase activity in liver. Increases intracellular fatty acids derived from hydrolysis of newly formed triglyceride stores.
Abbreviation
AADAC
UniProt
P22760
Host
Rabbit
Reactivity
Human
Immunogen
Recombinant protein of human AADAC
Target
AAAD; Aada; Aadac; Arylacetamide deacetylase (esterase) ; Arylacetamide deacetylase; CES5A1; DAC
Clonality
Polyclonal
Conjugation
Unconjugated
Applications
WB; IHC
Field of Research
Metabolism; Signal Transduction
Purification
Affinity purification
Concentration
0.2 mg/mL
Dilution
WB 1:500-1:2000; IHC 1:25-1:100
Buffer
PBS with 0.05% sodium azide and 50% glycerol, PH7.4
Shipping Conditions
The product is shipped with ice pack, upon receipt, store it immediately at the temperature recommended.
Storage Conditions
Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.
Calculated Molecular Weight
46kDa
Isotype
IgG
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
L1585-01B-AP 100 µL
LD78-beta (LD78 beta (1-70), 464.2, Chemokine (CC motif) Ligand 3-like 1, CCL3L1, D17S1718, G0/G1 Switch Regulatory Protein 19-2, G0S19-2, MGC12815, Small Inducible Cytokine A3-like 1 Precursor, SCYA3L1, Tonsillar Lymphocyte LD78 beta) (AP) discontinued
Ask
View Details